natgillin/translations-raw huggingface dataset:
Adverse events data in patients with Still's disease is based on a partially open-label and partially blinded, placebo-controlled study of 15 SJIA patients, treated for up to 1.5 years. 
Podatki o neželenih učinkih pri bolnikih s Stillovo boleznijo temeljijo na delno odprti in delno slepi, s placebom nadzorovani študiji na podlagi 15 bolnikov s SJIA, ki se zdravijo do 1,5 let.
Administration of Kineret results in a decrease in the acute phase reactants and a decrease in IL-6 expression level has been observed. 
Dajanje zdravila Kineret povzroča zmanjšanje reaktantov akutne faze in zaznano je zmanjšanje izražene ravni IL-6.
CIAS1/NLRP3 encodes for cryopyrin, a component of the inflammasome. 
CIAS1/NLRP3 tvori sporočilo za kriopirin, sestavino inflamasoma.
The therapeutic response is primarily reflected by reduction in clinical symptoms such as fever, rash, joint pain, and headache, but also in inflammatory serum markers (CRP/SAA levels), or occurrence of flares. 
Terapevtski odziv se kaže predvsem v zmanjšanju kliničnih simptomov, kot so vročina, izpuščaji, bolečina v sklepih in glavobol, vendar tudi v serumskih označevalcih vnetja (ravni CRP/SAA) ali pojavu izbruhov.
The recommended starting dose in all CAPS subtypes is 1-2 mg/kg/day by subcutaneous injection. 
Priporočeni začetni odmerek pri vseh podtipih CAPS je 1-2 mg/kg/dan s subkutanim injiciranjem.
In placebo-controlled RA studies with Kineret, treatment was associated with small reductions in the mean values for total white blood count and absolute neutrophil count (ANC). 
Nevtropenija V študijah RA z zdravilom Kineret, kontroliranih s placebom, je bilo zdravljenje povezano z majhnim znižanjem srednjih vrednosti vseh belih krvničk in absolutnega števila nevtrofilcev (ANC - „absolute neutrophil count“).
In clinical studies of RA, 775 patients treated with daily Kineret doses of 30 mg, 75 mg, 150 mg, 1 mg/kg or 2 mg/kg, there was an increase of 2.4% to 5.3% in total cholesterol levels 2 weeks after start of Kineret treatment, without a dose-response relationship. 
V kliničnih študijah RA je bilo 775 bolnikov zdravljenih z dnevnimi odmerki 30 mg, 75 mg, 150 mg, 1 mg/kg ali 2 mg/kg zdravila Kineret in 2 tedna po začetku zdravljenja z zdravilom Kineret se je raven skupnega holesterola povišala z 2,4 % na 5,3 %, neodvisno od odmerka.
How to use Kineret 
Kako uporabljati zdravilo Kineret
Both episodes of neutropenia resolved over time with continued Kineret treatment. 
Obe epizodi nevtropenije sta sčasoma prešli ob nadaljnji uporabi zdravila Kineret.
This section contains information on how to give yourself or your child an injection of Kineret. 
To poglavje vsebuje informacije o tem, kako injicirate zdravilo Kineret sebi ali svojemu otroku.
RA patients may be at a higher risk (on average 2-3 fold) for the development of lymphoma. 
Bolnike z RA bolj ogroža (v povprečju 2- do 3-krat bolj) pojav limfomov.
No overall differences in safety or effectiveness were observed between these patients and younger patients. 
V celoti gledano med temi bolniki in mlajšimi bolniki ni razlik glede varnosti ali učinkovitosti zdravila.
At Week 24, 6 of 12 patients on anakinra were in remission versus 2 of 10 patients on DMARDs. 
V 24. tednu je bilo v remisiji 6 od 12 bolnikov, ki so jemali anakinro, v primerjavi z 2 od 10 bolnikov, ki so jemali DMARD.
Adverse reactions are listed according to MedDRA system organ class and frequency category. 
Neželeni učinki so navedeni po skupinah organskih sistemov in kategorijah pogostnosti MedDRA.
These have shown no deleterious effect on joint cartilage. 
Le-te niso pokazale škodljivih učinkov na sklepni hrustanec.
Symptoms of infection might include a fever or a sore throat. 
Simptomi okužbe lahko obsegajo vročino ali vneto žrelo;
Very common side effects (may affect more than 1 in 10 people): - Redness, swelling, bruising or itching at the injection site. 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov): - rdečina, otekanje, modrica ali srbenje na mestu injiciranja.
It is recommended that neutrophil counts be assessed prior to initiating Kineret treatment, and while receiving Kineret, monthly during the first 6 months of treatment and quarterly hereafter. 
Priporočajo določanje nevtrofilcev pred uvedbo zdravljenja z zdravilom Kineret, med zdravljenjem z zdravilom Kineret pa prvih šest mesecev vsak mesec, nato pa na četrt leta.
Interleukin-1 (IL-1) is a pivotal pro-inflammatory cytokine mediating many cellular responses including those important in synovial inflammation. 
Interlevkin-1 (IL-1) je ključni vnetje pospešujoči citokin, ki posreduje številne celične odzive, med drugimi tudi tiste, ki so pomembni pri sinovialnem vnetju.
During post-marketing use events of interstitial lung disease, pulmonary alveolar proteinosis and pulmonary hypertension have been reported mainly in paediatric patients with Still's disease treated with IL-6 and IL-1 inhibitors, including Kineret. 
Med uporabo po začetku trženja so poročali o intersticijski bolezni pljuč, pljučni alveolarni proteinozi in pljučni hipertenziji, večinoma pri pediatričnih bolnikih s Stillovo boleznijo, ki so jih zdravili z zaviralci IL-6 in IL-1, vključno z zdravilom Kineret.
The clearance of anakinra in RA patients increased with increasing creatinine clearance. 
Očistek anakinre pri bolnikih z RA se je povečal s povečanjem očistka kreatinina.
• alcohol wipes or similar; and 
• alkoholne lističe ali podobno in • sterilno gazo ali robček
What you need to know before you use Kineret Do not use Kineret 
Kaj morate vedeti, preden boste uporabili zdravilo Kineret Ne uporabljajte zdravila Kineret:
The concurrent administration of Kineret and etanercept or other TNF-α antagonists is not recommended (see section 4.5). 
Sočasna uporaba zdravila Kineret in etanercepta ali drugih antagonistov TNF-α ni priporočljiva (glejte poglavje 4.5).
Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with Still's disease. 
Sinrom aktivacije makrofagov (MAS-macrophage activation syndrome) je znana življenjsko nevarno stanje, ki se lahko razvije pri bolnikih s Stillovo boleznijo.
Cutaneous, Articular Syndrome (CINCA) - Muckle-Wells Syndrome (MWS) - Familial Cold Autoinflammatory Syndrome (FCAS) 
(CINCA - Chronic Infantile Neurological, Cutaneous, Articular Syndrome) - Muckle-Wellsov sindrom (MWS) - družinski avtoinflamatorni sindrom zaradi mraza (FCAS - Familial Cold Autoinflammatory Syndrome)
Systemically, IL-1 is known to cause the hypothalamic fever response and promote hyperalgesia. 
Znano je, da IL-1 sistemsko povzroči hipotalamični odziv z zvišano telesno temperaturo in spodbudi hiperalgezijo.
- Serious infections such as pneumonia (a chest infection) or infections of the skin. 
- resne okužbe, na primer pljučnica (okužba v prsnem košu) ali okužbe kože;
The efficacy and safety of Kineret in patients with AST/ALT ≥ 1.5 x upper level of normal have not been evaluated. 
Učinkovitost in varnost zdravila Kineret pri bolnikih z vrednostjo AST/ALT ≥1,5 krat višjo od najvišje normalne vrednosti nista bili ocenjeni.
This would be clinically relevant for CYP450 substrates with a narrow therapeutic index (e.g. warfarin and phenytoin). 
CYP450 z ozkim terapevtskim indeksom (npr. varfarin in fenitoin).
Hold the syringe barrel and gently remove the cover from the needle without twisting. 
Primite telo brizge in previdno odstranite pokrovček z igle, ne da bi ga vrteli.
In 15 SJIA patients followed for up to 1.5 years, one patient developed a serious hepatitis in connection with a cytomegalovirus infection. 
Pri 15 bolnikih s SJIA, ki so jih spremljali do 1,5 leta, se je pri enem bolniku razvila resna oblika hepatitisa v povezavi s citomegalovirusno okužbo.
If you develop signs of an infection or worsening of your Still's disease symptoms you should contact your health care provider as soon as possible. 
Če se pojavijo znaki okužbe ali poslabšanja simptomov Stillove bolezni, se morate čim prej posvetovati z zdravnikom.
Additional published data in Still's disease indicate that Kineret induces a rapid resolution of systemic features such as fever, rash, and elevation of acute phase reactants. 
Dodatni objavljeni podatki o Stillovi bolezni kažejo, da zdravilo Kineret povzroči hitro rešitev sistemskih težav, kot so zvišana telesna temperatura, izpuščaj in povišanje reaktantov akutne faze.
In 43 CAPS patients followed for up to 5 years neutropenia was reported in 2 patients. 
Od 43 bolnikov s CAPS, ki so jih spremljali do 5 let, so o nevtropeniji poročali pri 2 bolnikih.
Still's disease - Patients with Still's disease may develop a condition called macrophage activation syndrome (MAS), which can be life-threatening. 
Stillova bolezen - Pri bolnikih s Stillovo boleznijo se lahko razvije bolezen, ki se imenuje sindrom aktivacije makrofagov (MAS), ki je lahko smrtno nevarna.
Kineret has not been tested in pregnant women. 
Pri nosečnicah zdravila Kineret niso preizkusili.
If you use more Kineret than you should 
Če ste uporabili večji odmerek zdravila Kineret, kot bi smeli
For CAPS, Kineret is used to treat the signs and symptoms of inflammation associated with the disease such as rash, joint pain, fever, headache and fatigue in adults and children (age 8 months and older). 
Pri CAPS se zdravilo Kineret uporablja za zdravljenje znakov in simptomov vnetja, povezanega z boleznimi, kot so izpuščaji, bolečina v sklepih, vročina, glavobol in utrujenost pri odraslih in otrocih (starih 8 mesecev in več).
During post-marketing use isolated case reports indicating non-infectious hepatitis have been received. 
V času uporabe po začetku trženja so se pojavili posamezni primeri, ki so kazali na neinfektivni hepatitis.
Kineret is injected just under the skin. 
Zdravilo Kineret se injicira tik pod kožo.
Adult 
Odrasla oseba
- Thrombocytopenia (low level of blood platelets). 
- trombocitopenija (nizka raven trombocitov v krvi).
Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone. 
Zdravilo Kineret je indicirano pri odraslih za zdravljenje znakov in simptomov RA v kombinaciji z metotreksatom pri bolnikih z nezadostnim odzivom na metotreksat sam.
The estimated anakinra clearance increased with increasing creatinine clearance and body weight. 
Ocenjeni očistek anakinre se je večal z rastočim očistkom kreatinina in s telesno maso.
The pre-filled syringe is for single use only. 
Napolnjena injekcijska brizga je samo za enkratno uporabo.
Neutropenia (ANC < 1.5 x 109/l) was reported in 2.4% patients receiving Kineret compared with 0.4% of placebo patients. 
O nevtropeniji (ANC < 1,5 x 109/l) so poročali pri 2,4 % bolnikov, ki so prejemali zdravilo Kineret, v primerjavi z 0,4 % pri bolnikih s placebom.
The development of ISRs in patients who had not previously experienced ISRs was uncommon after the first month of therapy. 
Pri bolnikih, ki prej niso imeli ISR, se je ISR po prvem mesecu zdravljenja razvila le izjemoma.
The safety and efficacy of Kineret have been demonstrated in CAPS patients with varying degrees of disease severity. 
Varnost in učinkovitost zdravila Kineret so dokazali pri bolnikih s CAPS z različnimi stopnjami izraženosti bolezni.
For RA, Kineret is used to treat the signs and symptoms of the disease in adults (age 18 years and over) in combination with another medicine called methotrexate. 
Pri RA se zdravilo Kineret uporablja za zdravljenje znakov in simptomov revmatoidnega artritisa pri odraslih (starih 18 let in več) v kombinaciji s še enim zdravilom, ki se imenuje metotreksat.
At the same time point, 7 of 12 in the Kineret treated group were classified as ACRpedi50 and 5 of 12 as ACRpedi70 responders compared to none in the placebo group. 
Na isti časovni točki je imelo 7 od 12 bolnikov v skupini, zdravljeni z zdravilom Kineret, odziv ACRpedi50 in 5 od 12 odziv ACRpedi70, v primerjavi z nobenim bolnikom v skupini, zdravljeni s placebom.
Neutrophil decreases occurred more frequently in patients receiving Kineret compared with placebo. 
Nevtrofilci so se znižali pogosteje pri bolnikih, ki so dobivali zdravilo Kineret, kot pri tistih, ki so prejemali placebo.
The infections observed consisted primarily of bacterial events such as cellulitis, pneumonia, and bone and joint infections. 
Zabeležene okužbe so obsegale predvsem bakterijske, npr. flegmono, pljučnico ter okužbe kosti in sklepov.
- In rare cases patients with Still's disease, mainly children, may develop lung disease, also during Kineret treatment. 
- V redkih primerih se lahko pri bolnikih s Stillovo boleznijo, predvsem pri otrocih, pojavi pljučna bolezen, tudi med zdravljenjem z zdravilom Kineret.
• the upper outer areas of the buttocks; and 
• zgornji zunanji del zadnjice in
In studies of sepsis, 1,015 patients received Kineret at doses up to 2 mg/kg/hour i.v. 
V študijah sepse je 1015 bolnikov dobivalo zdravilo Kineret v odmerkih do 2 mg/kg/uro i.v.
CAPS: Adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above 
CAPS: Odrasli, mladostniki, otroci in dojenčki, stari 8 mesecev in več, s telesno maso 10 kg ali več Začetni odmerek
Pack sizes of 1, 7 or 28 (multipack containing 4 packs of 7 pre-filled syringes) pre-filled syringes. 
Pakiranja po 1, 7 ali 28 (skupno pakiranje, ki vsebuje 4 ali 7 napolnjenih injekcijskih brizg) napolnjenih injekcijskih brizg.
These were typically characterised by 1 or more of the following: erythaema, ecchymosis, 
Običajno je bilo zanje značilno eno ali več od naslednjega: eritem, ekhimoza, vnetje in bolečina.
There are limited amount of data from the use of anakinra in pregnant women. 
Podatki o uporabi anakinre pri nosečnicah so omejeni.
What Kineret looks like and contents of the pack 
Izgled zdravila Kineret in vsebina pakiranja
For a small number of patients with asthma, the incidence of serious infection was higher in Kineret-treated patients (4.5%) vs. placebo-treated patients (0%), these infections were mainly related to the respiratory tract. 
Pri majhnem številu bolnikov z astmo je bila incidenca resnih okužb večja pri bolnikih, ki so dobivali zdravilo Kineret (4,5%), kot pri tistih, ki so dobivali placebo (0 %), te okužbe pa so se nanašale v glavnem na dihalne poti.
Hepatic events in patients with Still's disease predominantly occur during the first month of Kineret treatment. 
Jetrni zapleti pri bolnikih s Stillovo boleznijo se pretežno pojavijo v prvem mesecu zdravljenja z zdravilom Kineret.
There are no indications from post-marketing experience that types and severity of infections in patients with Still's disease differ from those in RA or CAPS patients. 
Iz izkušenj med uporabo po začetku trženja ni indikacij, da bi bile vrste in jakost okužb pri bolnikih s Stillovo boleznijo drugačne kot pri bolnikih z RA ali CAPS.
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice. 
Če imate kakršne koli težave, brez obotavljanja prosite za pomoč in nasvet zdravnika ali medicinsko sestro.
Prior to launch of the new indication Still's disease for Kineret in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, 
Pred uvedbo nove indikacije za zdravilo Kineret za Stillovo bolezen v vsaki državi članici mora imetnik dovoljenja za promet z zdravilom (MAH) z nacionalnim pristojnim organom uskladiti vsebino in obliko izobraževalnega programa, vključno s sredstvi obveščanja, načini razdeljevanja in vsemi drugimi vidiki programa.
• The prescribed dose of Kineret 
• predpisani odmerek zdravila Kineret,
The mean plasma clearance of Kineret in subjects with mild (creatinine clearance 50-80 ml / min) and moderate (creatinine clearance 30-49 ml/min) renal insufficiency was reduced by 16% and 50%, respectively. 
Srednji plazemski očistek zdravila Kineret pri osebah z blago (očistek kreatinina 50-80 ml/min) in zmerno ledvično insuficienco (očistek kreatinina 30-49 ml/min) je bil zmanjšan za 16 % oziroma
There are no indications either from this study or from post-marketing adverse reaction reports that the overall safety profile in patients with CAPS or Still's disease is different from that in patients with RA, with the exception of the risk for development of MAS in patients with Still's disease. 
Glede na to študijo ali poročila o neželenih učinkih med uporabo po začetku trženja ni nobenih znakov, da je splošni varnostni profil pri bolnikih s CAPS ali Stillovo boleznijo drugačen kot pri bolnikih z RA, z izjemo tveganja za razvoj MAS pri bolnikih s Stillovo boleznijo.
Each graduated pre-filled syringe contains 100 mg of anakinra* per 0.67 ml (150 mg/ml). 
Ena odmerna napolnjena injekcijska brizga vsebuje 100 mg anakinre* na 0,67 ml (150 mg/ml).
You must not be given live vaccines while being treated with 
Živih cepiv zato ne smete uporabljati sočasno z zdravilom
In 43 CAPS patients followed for up to 5 years no patient permanently or temporarily discontinued Kineret treatment due to injection site reactions. 
Od 43 bolnikov s CAPS, ki so jih spremljali do 5 let, ni bilo pri nobenem bolniku trajno ali začasno prekinjeno zdravljenje z zdravilom Kineret zaradi reakcij na mestu injiciranja.
In severe renal insufficiency and end stage renal disease (creatinine clearance < 30 ml/min), mean plasma clearance declined by 70% and 75%, respectively. 
Pri hudi ledvični insuficienci in končni ledvični odpovedi (očistek kreatinina < 30 ml/min) se je srednji plazemski očistek zmanjšal za 70 % oz. 75 %.
The subject incidence of serious adverse reactions in RA studies at the recommended dose of Kineret (100 mg/day) was comparable with placebo (7.1% compared with 6.5% in the placebo group). 
Incidenca resnih neželenih učinkov v študijah RA pri priporočenem odmerku zdravila Kineret (100 mg/dan) je bila primerljiva s placebom (7,1 % v primerjavi s 6,5 % v skupini s placebom).
Data from mice over expressing IL-1ra and IL-1ra mutant knock-out mice, did not indicate an increased risk of tumour development. 
Podatki, pridobljeni na transgenih miših s prekomerno ekspresijo IL-1ra in tistih z mutiranim IL-1ra niso pokazali zvečane nevarnosti za razvoj tumorjev.
• the top of the thighs 
• zgornji del stegen
CAPS: Data in elderly patients are limited. 
CAPS: Podatki o starejših bolnikih so omejeni.
Kineret contains the active substance anakinra. 
Zdravilo Kineret vsebuje učinkovino anakinra.
It is unknown whether anakinra/metabolites are excreted in human milk. 
Ni znano, ali se anakinra/presnovki izločajo v materino mleko.
Possible side effects are similar regardless if you are treated with Kineret for RA, CAPS or Still's disease. 
Možni neželeni učinki so podobni, ne glede na to, ali se zdravite z zdravilom Kineret zaradi RA, CAPS ali Stillove bolezni.
Allergic reactions, including anaphylactic reactions and angioedema have been reported uncommonly. 
Občasno so poročali o alergijskih reakcijah, vključno z anafilaktičnimi reakcijami in angioedemom.
In placebo-controlled studies in RA patients, the most frequently reported adverse reactions with Kineret were injection site reactions (ISRs), which were mild to moderate in the majority of patients. 
V s placebom kontroliranih študijah pri bolnikih z RA so bili neželeni učinki pri zdravilu Kineret, o katerih so najpogosteje poročali, reakcije na mestu injiciranja (ISR - „injection site reaction“), ki so bile pri večini bolnikov blage do zmerne.
Undesirable Effect 
Možni neželeni učinki
In Kineret treated CAPS patients, there is a risk for disease flares when discontinuing Kineret treatment. 
Pri bolnikih s CAPS, zdravljenih z zdravilom Kineret, obstaja tveganje za izbruh bolezni po prekinitvi zdravljenja s tem zdravilom.
This medicine contains less than 1 mmol sodium (23 mg) per 100 mg dose, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 100 mg, kar v bistvu pomeni „brez natrija“.
Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. 
Zdravilo Kineret je indicirano pri odraslih, mladostnikih, otrocih in dojenčkih, starih 8 mesecev in več, s telesno maso 10 kg ali več, za zdravljenje Stillove bolezni, vključno s sistemskim juvenilnim idiopatskim artritisom (SJIA - Systemic Juvenile Idiopathic Arthritis) in Stillovo boleznijo z začetkom v odrasli dobi (AOSD - Adult-Onset Still's Disease), z aktivnimi sistemskimi značilnostmi zmerne do visoke aktivnosti bolezni, ali pri bolnikih z neprekinjeno aktivnostjo bolezni po zdravljenju z nesteroidnimi protivnetnimi zdravili (NSAID) ali glukokortikoidi.
Concurrent Kineret and etanercept treatment has not demonstrated increased clinical benefit. 
Sočasno zdravljenje z zdravilom Kineret in etanerceptom ni pokazalo zvečane klinične koristnosti.
As a precautionary measure, it is preferable to avoid the use of anakinra during pregnancy and in woman of childbearing potential not using contraception. 
Iz previdnostnih razlogov se je med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije, uporabi anakinre bolje izogibati.
What should you do before you give yourself or your child a subcutaneous injection of Kineret? 
Kaj morate narediti, preden daste podkožno injekcijo zdravila Kineret sebi ali svojemu otroku?
No data are available on either the effects of live vaccination or on the secondary transmission of infection by live vaccines in patients receiving Kineret. 
O učinkih živih cepiv in o sekundarnem prenosu okužbe z živimi cepivi pri bolnikih, ki so dobivali zdravilo Kineret, ni nobenih podatkov.
The safety and efficacy of Kineret treatment in patients with chronic and serious infections have not been evaluated. 
Varnosti in učinkovitosti zdravila Kineret pri bolnikih s kroničnimi in resnimi okužbami niso ovrednotili.
Overall, the efficacy and safety profile of Kineret is comparable in adult and paediatric patients with CAPS or Still's disease. 
Pediatrična populacija V celoti sta učinkovitost in varnostni profil zdravila Kineret primerljiva pri odraslih in pediatričnih bolnikih s CAPS ali Stillovo boleznijo.
Solution for injection in pre-filled syringe 7 GRADUATED pre-filled syringes This box containing 7 pre-filled syringes is part of a 28-multipack. 
raztopina za injiciranje v napolnjeni injekcijski brizgi 7 ODMERNIH napolnjenih injekcijskih brizg Ta škatla s 7 napolnjenimi injekcijskimi brizgami je del pakiranja po 28.
The majority of patients have been treated for Still's disease or have had predisposing factors, e.g. a history of transaminase elevations. 
Večina bolnikov je bila zdravljena za Stillovo bolezen ali je imela predispozicijske dejavnike, npr.
The safety and efficacy of Kineret in patients with neutropenia have not been evaluated. 
Varnosti in učinkovitosti zdravila Kineret pri bolnikih z nevtropenijo niso ovrednotili.
Kineret treatment must not be initiated in patients with neutropenia (ANC <1.5 x 109/l) (see section 4.4). 
Zdravila Kineret se ne sme uvesti pri bolnikih z nevtropenijo (ANC < 1,5 x 109/l) (glejte poglavje 4.4).
Change the place that you inject each time so you don't become sore in one area. 
Mesto injiciranja vsakokrat zamenjajte, tako da se en predel ne bo razbolel.
After a 1-month blinded phase, 8 of 12 patients in the Kineret treated group were identified as modified ACRpedi30 responders compared to 1 of 12 in the placebo group. 
Po 1-mesečni slepi fazi je bilo ugotovljeno, da je imelo spremenjeni odziv ACRpedi30 8 od 12 bolnikov v skupini, ki se je zdravila z zdravilom Kineret, v primerjavi z 1 od 12 bolnikov v skupini, zdravljeni s placebom.
CAPS: Posology and administration in children and infants aged 8 months and older with a body weight of 10 kg or above are the same as for adult CAPS patients, based on body weight. 
CAPS: Odmerjanje in dajanje otrokom in dojenčkom, starim 8 mesecev in več s telesno maso 10 kg ali več je enako kot pri odraslih bolnikih s CAPS in temelji na telesni masi.